These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
521 related articles for article (PubMed ID: 36914208)
1. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors. Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208 [TBL] [Abstract][Full Text] [Related]
2. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256 [TBL] [Abstract][Full Text] [Related]
3. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. Kosti P; Maher J; Arnold JN Front Immunol; 2018; 9():1104. PubMed ID: 29872437 [TBL] [Abstract][Full Text] [Related]
4. NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors. Nakagawara K; Ando M; Srirat T; Mise-Omata S; Hayakawa T; Ito M; Fukunaga K; Yoshimura A J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39151930 [TBL] [Abstract][Full Text] [Related]
6. rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors. Li D; Liang T; Hutchins LE; Wolfarth AA; Ferrando-Martinez S; Lee BH; Ho M J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39043602 [TBL] [Abstract][Full Text] [Related]
7. Altered cancer metabolism and implications for next-generation CAR T-cell therapies. Ramapriyan R; Vykunta VS; Vandecandelaere G; Richardson LGK; Sun J; Curry WT; Choi BD Pharmacol Ther; 2024 Jul; 259():108667. PubMed ID: 38763321 [TBL] [Abstract][Full Text] [Related]
8. Coengineering specificity, safety, and function into T cells for cancer immunotherapy. Giordano Attianese GMP; Ash S; Irving M Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063 [TBL] [Abstract][Full Text] [Related]
9. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors. Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342 [TBL] [Abstract][Full Text] [Related]
10. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors. Sloas C; Gill S; Klichinsky M Front Immunol; 2021; 12():783305. PubMed ID: 34899748 [TBL] [Abstract][Full Text] [Related]
11. How to Test Human CAR T Cells in Solid Tumors, the Next Frontier of CAR T Cell Therapy. Cochrane RW; Fiorentino A; Allen E; Robino RA; Quiroga J; Ferreira LMR Methods Mol Biol; 2024; 2748():243-265. PubMed ID: 38070118 [TBL] [Abstract][Full Text] [Related]
12. Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors. Rodriguez-Garcia A; Watanabe K; Guedan S Methods Mol Biol; 2020; 2086():251-271. PubMed ID: 31707682 [TBL] [Abstract][Full Text] [Related]
13. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Martinez M; Moon EK Front Immunol; 2019; 10():128. PubMed ID: 30804938 [TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
15. Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor. Gao G; Liao W; Shu P; Ma Q; He X; Zhang B; Qin D; Wang Y J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37591632 [TBL] [Abstract][Full Text] [Related]
16. Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor. Myers Chen K; Grun D; Gautier B; Venkatesha S; Maddox M; Zhang AH; Andersen P Front Immunol; 2024; 15():1380065. PubMed ID: 38726005 [TBL] [Abstract][Full Text] [Related]
17. [T cell-based immunotherapies in solid tumors]. Baulu E; Dougé A; Chuvin N; Bay JO; Depil S Bull Cancer; 2021 Oct; 108(10S):S96-S108. PubMed ID: 34920813 [TBL] [Abstract][Full Text] [Related]
18. Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells. Vincent RL; Li F; Ballister ER; Arpaia N; Danino T J Vis Exp; 2024 Feb; (204):. PubMed ID: 38372353 [TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors. Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133 [TBL] [Abstract][Full Text] [Related]